Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium

Doris K. Hansen, Surbhi Sidana, Lauren C. Peres, +22

Journal of Clinical Oncology

Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy

Christopher J. Ferreri, Michelle A.T. Hildebrandt, Hamza Hashmi, +26

Blood Cancer Journal

Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma

Surbhi Sidana, Krina K. Patel, Lauren C. Peres, +35

Blood

Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance

Saad Z. Usmani, Rachel Sexton, Antje Hoering, +11

Blood

Patterns of Central Nervous System Involvement in Relapsed and Refractory Multiple Myeloma

Al‐Ola Abdallah, Shebli Atrash, Zainab Shahid, +11

Clinical Lymphoma Myeloma & Leukemia

Hematological MalignancyNeuro-oncologyPathologyNeurologyMultiple Sclerosis +4

Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma

Rashid Khan, Senu Apewokin, Monica Grazziutti, +12

Leukemia

Renal PathologyTransplantation MedicineRenal InflammationHematological MalignancyRenal Function +19

Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Luciano J. Costa, Shaji Kumar, Shebli Atrash, +16

Blood

Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment

Surbhi Sidana, Lauren C. Peres, Hamza Hashmi, +28

Haematologica

Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM).

Doris K. Hansen, Krina K. Patel, Lauren C. Peres, +17

Journal of Clinical Oncology

Hematological MalignancyOncologyHealth SciencesCiltacabtagene AutoleucelIntended Soc Cilta-cel +13

Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma: U.S. Myeloma Immunotherapy Consortium real world experience

Hamza Hashmi, Doris K. Hansen, Lauren C. Peres, +23

Haematologica